secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001628280-25-034890
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive obtains Health Canada meeting for Anaphylm NDS; EMA briefing book submitted
--------------------------------------------------------------------------------

- Health Canada grants Q3 2025 meeting for planned New Drug Submission of Anaphylm (epinephrine) Sublingual Film.
- Initial briefing book submitted to European Medicines Agency; MA submission planned as soon as possible.
- U.S. NDA accepted with PDUFA target action date of January 31, 2026.
- Company pursuing parallel ex-U.S. regulatory pathways for needle-free, device-free anaphylaxis treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025034890/0001628280-25-034890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025034890/aqst-20250715.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-034890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer